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ABSTRACT 
 
The human epidermal growth factor receptor 3 (HER3) is over-expressed in several cancers, 
being linked to a more resistant phenotype and hence poor patient prognosis. Imaging HER3 
is challenging owing to the modest receptor number (<50000 receptors/cell) in 
overexpressing cancer cells. Therefore, to image HER3 in vivo, high target affinity PET 
probes need to be developed. This work describes two different [
18
F]AlF radiolabeling 
strategies of the ZHER3:8698 affibody molecule specifically targeting HER3. The one-pot 
radiolabeling of ZHER3:8698 performed at 100ºC and using 1,4,7-triazanonane-1,4,7-triacetate 
(NOTA) as chelator resulted in radiolabeled products with variable purity attributed to the 
radioconjugate thermolysis. An alternative approach based on the inverse electron demand 
Diels-Alder (IEDDA) reaction between a novel tetrazine functionalized 1,4,7-
triazacyclononane-1,4-diacetate (NODA) chelator and the trans-cyclooctene (TCO) 
functionalized affibody molecule was also investigated. This method enabled the 
radiolabeling of the protein at room temperature. The [
18
F]AlF-NOTA-ZHER3:8698 and 
[
18
F]AlF-NODA-ZHER3:8698 conjugates showed a specific uptake at 1 h after injection in high 
HER3-expressing MCF-7 tumors of 4.36 ± 0.92 % ID/g and 4.96 ± 0.65 % ID/g respectively. 
The current results are encouraging for further investigation of [
18
F]AlF-NOTA-ZHER3:8698 as 
a HER3 imaging agent. 
 
INTRODUCTION 
 
HER3 is a member of the human epidermal growth factor receptor (EGFR/HER) tyrosine 
kinase family. Its overexpression has been found in a wide variety of cancers including 
breast, ovary, lung, and head and neck cancer.
1
 Multiple studies have highlighted HER3 as a 
fundamental receptor involved in the establishment of malignancy, demonstrating that HER3 
overexpression correlates with advanced disease stage and decreased overall survival.
2-7
 
Moreover, signaling by HER3 has recently been identified as a prominent mediator of tumor 
resistance to HER1 and HER2-targeted therapies.
1, 8-11
 This has driven the development of 
HER3-targeting monoclonal antibodies (mAbs), some of which have already entered clinical 
trials.
12-15
 However, the lack of suitable biomarkers to evaluate HER3 status impedes the 
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effective patient selection for these therapies. Radionuclide-based molecular imaging of 
HER3 receptor expression could guide patient stratification for HER3 targeted therapies, and 
more importantly aid monitoring early tumor response to therapeutic intervention. Recently, 
anti-HER3 mAbs and F(ab')2 fragments were radiolabeled with 
64
Cu and 
89
Zr for molecular 
imaging of HER3 expression.
16-18
 Additionally, a 
89
Zr radiolabeled mAb (GSK2849330) is 
currently under evaluation in patients with advanced solid tumors (clinical trial identifier: 
NCT12345174). However, clinical application of full-length radiolabeled antibodies as 
imaging agents is not optimal because of their long biological half-life and relatively poor 
tumor penetration which can affect image quality. By contrast, affibody molecules undergo 
rapid clearance as a result of their smaller size (ca 7 kDa), with elimination mainly through 
the kidneys, increasing the tumor-to-background ratio. Affibody molecules are non-toxic 
scaffold small proteins characterized by a high binding affinity (Kd in the low-nanomolar to 
picomolar range) and high target specificity. Furthermore, the introduction of a unique 
cysteine residue at the C-terminus of the molecules allows the site-specific conjugation of 
chelators, dyes or radiolabeled groups to the protein.
19, 20
 The high affinity affibody molecule 
ZHER3:8698 has been previously selected and radiolabeled with the single photon emission 
computed tomography (SPECT) radioisotopes 
99m
Tc and 
111
In in order to image HER3 
expression in vivo.
21-23
 To successfully visualize the receptor, the authors had to overcome a 
variety of challenges including the modest overexpression of the HER3 target (ca 50000 
receptors/cell in high-expressing cell lines such as BT-474) and the natural high expression of 
HER3 in normal organs and tissues (such as intestine, salivary glands and lung).
22, 24
 
Additionally, the same research group reported that the affibody molecule uptake in tumors 
having modest receptor overexpression is highly influenced by the injected protein dose. 
They identified 1 µg of radiolabeled protein to be the optimal quantity for HER3 imaging, 
since higher amounts, associated to lower specific activity, resulted in diminished tumor 
uptake.
25
his study describes the development of affibody-based agents suitable for 
18
F 
positron emission tomography (PET) imaging of HER3-expression. Because of its half-life 
(109 minutes), the PET radionuclide fluorine-18 is more compatible with the 
pharmacokinetics of the affibody molecule than SPECT radioisotopes enabling the 
acquisition of high quality PET images at 1-3 hours post injection. The affibody molecule 
ZHER3:8698 was radiolabeled using the rapid and efficient aluminum 
18
F-fluoride ([
18
F]AlF) 
approach, based on the formation of a stable 
18
F-aluminum bond, and consequent 
coordination by macrocyclic ligands.
26, 27
 The [
18
F]AlF radiolabeling method can be 
performed in a single step (one-pot reaction) and it has been used to successfully radiolabel a 
variety of peptides and proteins including affibody molecules.
28-35
 Two different 
radiolabeling strategies were investigated to establish the best protocol for a reproducible 
production of [
18
F]AlF radiolabeled ZHER3:8698 suitable for imaging HER3 expression. Firstly, 
the synthesis reported in the literature using NOTA as the chelator for the [
18
F]AlF complex 
was followed.
36
 Secondly, the inverse electron demand Diels-Alder (IEDDA) reaction to 
radiolabel the affibody molecule under mild reaction conditions in a two-step method was 
adopted. McBride et al. reported the radiolabeling of a heat-sensitive antibody Fab’ fragment 
using the maleimide functionalized 1,4,7-triazacyclononane-1,4-diacetate chelator (NODA-
MPAEM) which was mixed with Al
3+
 and [
18
F]F
-
 and then conjugated to the reduced thiol 
group of the protein.
37
 Kiesewetter et al. employed a similar maleimide-thiol conjugation 
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approach to synthesize the affibody-based radioconjugate [
18
F]FBEM-ZHER2:342. A limitation 
of this approach is that an initial reduction of the thiol group of the terminal cysteine of the 
affibody molecule was required as part of the radiolabeling protocol. The reducing agent had 
to be removed by size exclusion chromatography prior to conjugation of the reduced affibody 
molecule with the maleimide functionalized prosthetic group; as a result, the radiolabeling 
reaction lasted more than an hour and required multiple purification steps.
38
 The IEDDA 
reaction is an attractive alternative to the maleimide-thiol conjugation because it eliminates 
the need for the reduction step as part of the radiolabeling procedure. This approach, which is 
based on the reaction between a tetrazine and a strained cycloalkene, is chemospecific, 
proceeds in aqueous medium at room temperature, and forms stable products with negligible 
side products.
39
 These characteristics have prompted an increased interest in IEDDA 
reactions for bioconjugation as well as pretargeting purposes.
39-41
 To perform this synthetic 
methodology, the novel [
18
F]AlF-3, containing the NODA chelator instead of NOTA, was 
prepared and subsequently reacted with the TCO-functionalized-affibody molecule at room 
temperature via an IEDDA reaction. This methodology enables the radiofluorination of heat-
sensitive compounds. 
The two different strategies described above were developed for the [
18
F]AlF radiolabeling of 
the HER3 targeting affibody molecule ZHER3:8698 with a particular focus on protein stability 
and radiolabeling efficiency (expressed as specific activity of the final radiocojugates). The 
performance in vitro and in vivo of both radioligands has been further compared using high 
HER3-expressing MCF-7 human breast cancer cells and tumor xenografts.  
 
RESULTS AND DISCUSSION 
 
Synthesis of the affibody conjugates. When analyzed by RP-HPLC, the affibody molecule 
having a cysteine residue at its C-terminus (ZHER3:8698-Cys) was observed to be present in 
solution mostly in a dimeric form due to the formation of an intermolecular disulfide bond 
(Figure S1A). In order to proceed with the conjugation using the maleimide functionalized 
NOTA or TCO, the affibody dimer required reduction to its monomeric free sulfhydryl form 
(Figure S1B). Different protocols described in the literature use an excess of a reducing agent 
such as DTT or TCEP-HCl which is then removed by gel permeation chromatography using 
either NAP-5 or Zeba columns just before proceeding to the conjugation reaction.
38, 42
 When 
such procedures were followed for the present study, the outcome was a substantial loss of 
affibody molecule because of the similarity between its molecular weight and the MWCO of 
the columns. The protein loss was found to be more prominent when low sample volumes 
and low protein concentrations were used. Moreover, the protein was usually recovered from 
size exclusion columns in a more diluted solution requiring the addition of a molar excess of 
maleimide functionalized compounds (i.e. MMA-NOTA and TCO-PEG3-Maleimide) which 
had to be subsequently removed by gel permeation chromatography. Added to the loss of 
protein, this overall multi-step process was found to be time consuming and required the use 
of multiple size exclusion columns. To improve the product yield and simplify its 
purification, a one-pot conjugation reaction was developed using TCEP-HCl as the reducing 
agent, which was not removed from the mixture. A quantitative yield of the products NOTA-
ZHER3:8698 and TCO-ZHER3:8698 in the shortest time possible was thus achieved, indicated by 
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the disappearance of the starting material when analyzed by RP-HPLC (Figures S1, S2A and 
S3A). To attain extremely pure products for the radiolabeling reaction, a single final 
purification of the conjugates by semi-preparative RP-HPLC was performed (Figures S2B 
and S3B). Following this optimized synthetic method, the pure products were obtained in a 
ca 60% and ca 45% yield for NOTA-ZHER3:8698 and TCO-ZHER3:8698 conjugates respectively 
compared to the 15-30% yield obtained when conventional methods were utilized. All 
products were characterized by MALDI-mass spectrometry (Supporting Information). 
 
Synthesis of NODA-tetrazine (3). The design of the tetrazine-chelator construct was 
dictated by the hydrophilicity of the final affibody conjugate and the synthetic accessibility of 
the chosen tetrazine. Therefore, a small molecular weight tetrazine-chelator having the 
closest structure to MMA-NOTA was developed. The non-commercially available tetrazine 1 
was synthesized in a simple one step process following a literature procedure.
43
 The NODA 
macrocycle was selected because it showed a higher labeling efficiency compared to NOTA, 
believed to be caused by the absence of a destabilizing electron-withdrawing carbonyl 
adjacent to a coordinating nitrogen atom of the macrocycle.
41
 The tosylated tetrazine 2 was 
reacted with NO2AtBu and subsequently deprotected using TFA yielding the NODA-
containing tetrazine 3 (Scheme 1). The final product was purified by RP-HPLC to ensure a 
high purity material for the subsequent radiolabeling (Figure S4).  
 
Scheme 1. Preparation of tetrazines 2 and 3 and radiolabelling of tetrazine 3. 
 
 
Reaction conditions: (a) p-toluenesulfonyl chloride, 16 h, rt; (b) NO2AtBu, DIPEA, 24 h, rt; (c) TFA, 3h, rt. (d) 
AlCl3, [
18
F]F
-
, sodium acetate/ethanol 1:1 (v/v), pH4, 15 min, 100ºC 
 
[
18
F]AlF radiolabeling of NOTA-ZHER3:8698 and NODA-ZHER3:8698. The two different 
radiochemical methodologies investigated for the radiolabeling of ZHER3:8698 with the 
[
18
F]AlF complex are shown in Scheme 2. Initially, a conventional direct radiolabeling 
strategy of the NOTA-ZHER3:8698 affibody conjugate was carried out with [
18
F]AlF in a one-
pot reaction at pH 4, 100ºC for 15 min using ethanol as organic co-solvent (50% v/v) as the 
addition of a hydrophilic organic solvent showed to increase the radiolabeled product yield.
32, 
33, 36
 The radiochemical conversion and the specific activity of the radioconjugate were 38.8 ± 
5.8 % (non-decay corrected) and 0.8-1.5 MBq/µg (6.0-11.9 GBq/µmol) respectively (Figure 
S13). 
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Scheme 2. Preparation of radioconjugates [
18
F]AlF-NOTA-ZHER3:8698 (A) and [
18
F]AlF-
NODA-ZHER3:8698 (B).  
 
Reaction conditions: (a) TCEP-HCl, MMA-NOTA, PBS; (b) AlCl3, [
18
F]F
-
, sodium acetate/ethanol 1:1 (v/v), 
pH4, 15 min, 100ºC; (c) TCEP-HCl, TCO-PEG3-Maleimide, PBS; (d) 17 min, rt. 
 
Mirroring Glaser et al., it was observed that optimal radiolabeling efficiencies were achieved 
by heating the [
18
F]AlF-complexation reaction at 100°C in conjunction with the formation of 
a by-product assumed to originate from the decomposition of the radioconjugate (Figure 
1A).
33
 Therefore, a procedure comprising of RP-HPLC followed by HLB-SPE purification 
was developed to produce [
18
F]AlF-NOTA-ZHER3:8698  with a RCP > 98% verified by HPLC 
(Figure 1B and Figure S5). To confirm its purity, the isolated product was analyzed using 
radio-SDS-PAGE and silver staining. Only one band corresponding to the molecular weight 
of the monomeric affibody molecule was detected on the gel autoradiography. No other 
bands which could indicate aggregation of the radioconjugate (high molecular weight 
compounds) or degradation (low molecular weight species) were observed (Figure S15).  
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Figure 1. Radiochromatograms of [
18
F]AlF-NOTA-ZHER3:8698 reaction mixture (A) and 
isolated product (B). Free 
18
F-fluoride and the radioconjugate elute with a Rt of 3:25 and 8:28 
respectively. The peak with Rt 4:22 is the side-product from the thermolysis. The retention 
times (Rt) are expressed as min:sec. 
 
The alternative two-step approach first required the radiolabeling of the tetrazine-bearing 
NODA chelator (3) with the [
18
F]AlF complex followed by the IEDDA reaction with the 
TCO-functionalized ZHER3:8698 affibody molecule (Scheme 2). Crucially, the mild conjugation 
conditions used in the IEDDA reaction can limit the formation of the by-product (Figure 1A, 
product eluting at 4:22) caused by the exposure of the conjugate to the high temperatures 
required for radiolabeling step. [
18
F]AlF-3 was prepared in high RCC (70-95%, calculated by 
HPLC and non-decay corrected) in a one pot reaction using ethanol as organic co-solvent 
(50% v/v). To confirm the hydrophilicity of [
18
F]AlF-3, its distribution coefficient (logD) 
between PBS (pH 7.4) and n-octanol was determined (Supporting Information). The logD7.4 
was found to be -1.87 ± 0.01 which confirmed that the product possessed suitable 
hydrophilicity for further investigation. The radio-HPLC of [
18
F]AlF-3 shows the presence of 
predominantly the two species [
18
F]AlF-3A and [
18
F]AlF-3B (Figure 2). When analyzed 
immediately after the end of reaction, the mixture was composed of mainly the product 
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eluting at 7 min 55 seconds ([
18
F]AlF-3B) with a minimal amount of product having a 
retention time of 7 min 11 seconds ([
18
F]AlF-3A). The [
18
F]AlF-3B/A ratio (based on peak 
areas) was found to be generally in the range of 11-23. After 2 hours, the ratio decreased to as 
little as 0.26 indicating that [
18
F]AlF-3B converted into [
18
F]AlF-3A over time, although not 
completely. The same behavior was observed when the radiolabeling was carried out in 
buffer without ethanol (Figure S6). Alternative organic co-solvents to ethanol (i.e. 
acetonitrile, tert-butanol) produced the same number of [
18
F]AlF-3 forms which surprisingly 
did not convert over time (Figure S7 and S8). A similar NODA-derivative, lacking the 
tetrazine moiety, showed a single radioactive product when radiolabeled and analyzed by RP-
HPLC (data not shown) indicating the involvement of the tetrazine in the generation of the 
two species. This was further confirmed by the formation of a comparable set of products 
when a similar compound, but having a longer linker between the NODA chelator and the 
tetrazine moiety, was radiolabeled and analyzed by RP-HPLC (data not shown).  
 
 
Figure 2. Radiochromatograms of [
18
F]AlF-3 as a mixture of [
18
F]AlF-3A and [
18
F]AlF-3B. 
The alteration in composition is depicted as a function of time. In the displayed representative 
radiotraces, the [
18
F]AlF-3B/A ratio is 23.4 immediately after the end of the reaction (I.) and 
it decreases to 1.36 after 2 h, rt (II.). The retention times (Rt) are expressed as min:sec. 
 
The precise molecular structures for [
18
F]AlF-3A and [
18
F]AlF-3B are uncertain at present 
and will be the subject of further study. 
Non-purified [
18
F]AlF-3 was reacted with lyophilized TCO-ZHER3:8698 in a 7:1 molar ratio at 
room temperature yielding the product almost quantitatively (Figure S9). RP-HPLC followed 
by HLB-SPE were used to purify the final product [
18
F]AlF-NODA-ZHER3:8698 from the 
excess of [
18
F]AlF-3 and free 
18
F-fluoride. As shown in Figure 3 and Figure S10, the IEDDA 
reaction yielded two radiolabeled products identified by HPLC.  
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Figure 3. Radiochromatogram of isolated [
18
F]AlF-NODA-ZHER3:8698. The retention times 
(Rt) are expressed as min:sec. 
 
At this stage, an investigation on whether the formation of the IEDDA adducts was 
dependent on the species composition of [
18
F]AlF-3 was carried out. [
18
F]AlF-3A and 
[
18
F]AlF-3B were hence collected separately by HPLC and, after confirming that no 
conversion was occurring once isolated (Figure S11), they were incubated with an excess of 
TCO-ZHER3:8698. HPLC analysis of the reaction mixtures showed that [
18
F]AlF-3A did not 
react with TCO-ZHER3:8698 even after 4 hours (Figure S12A). Conversely, [
18
F]AlF-3B reacted 
with the TCO-affibody conjugate generating the previously described multiple peaks pattern 
(Figure 3 and Figure S12B). The reason behind the inactivity of product [
18
F]AlF-3A is under 
investigation. To reduce its effect on the yield of the final radioconjugate, it was necessary to 
either add the freshly prepared [
18
F]AlF-3 to TCO-ZHER3:8698 promptly or synthesize [
18
F]AlF-
3 using an alternative organic co-solvent to ethanol to prevent species interconversion.  
The two peaks from the IEDDA adduct [
18
F]AlF-NODA-ZHER3:8698 were collected separately 
by HPLC and investigated further. When the peak having a Rt of 9 min (Peak 1, Figure 3) 
was reinjected, one single product with matching retention time to the one in the original 
separation was detected (Figure S13A). Attempts to isolate the peak at 10 min 36 sec (Peak 2, 
Figure 3) were unsuccessful. Each trial resulted in a mixture of the two peaks suggesting that 
Peak 2 partially transforms into Peak 1 over time (Figure S13B). Selvaraj et al suggested that 
by reacting with water, the IEDDA ligation product [
18
F]AlF-NODA-ZHER3:8698-
Dihydropyridazine undergoes a series of structural rearrangements that ultimately leads to the 
stable aromatic [
18
F]AlF-NODA-ZHER3:8698-Pyridazine (Scheme 3).
44
 Therefore, when 
analyzed by HPLC the radioconjugate is present as a combination of the aromatized 
[
18
F]AlF-NODA-ZHER3:8698-Pyridazine (Peak 1, Figure 3) and of [
18
F]AlF-NODA-ZHER3:8698-
Dihydropyridazine (Peak 2, Figure 3). Furthermore, when [
18
F]AlF-NODA-ZHER3:8698 was 
analyzed as a mixture by radio-SDS-PAGE only a single band with a comparable molecular 
weight to the ZHER3:8698 affibody was visible. This indicated that neither of the two products 
(Peak1 and Peak2) was the result of either aggregation or degradation of the protein (Figure 
S17). [
18
F]AlF-NODA-ZHER3:8698 was isolated in high radiochemical purity exceeding 98% 
(Figure 3) and the specific activity was in general higher than the NOTA radioconjugate but 
over a large range (0.7-2.3 MBq/µg; 5.5-18.4 GBq/µmol) (Figure S14) which may be due to 
the inconsistent quantity of inert product present in [
18
F]AlF-3. To investigate the impact of 
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the IEDDA ligation adduct on [
18
F]AlF-NODA-ZHER3:8698 hydrophilicity, its logD7.4 value 
was determined and compared to [
18
F]AlF-NOTA-ZHER3:8698 (Supporting Information). The 
logD7.4 for [
18
F]AlF-NODA-ZHER3:8698 was found to be hydrophilic with a value of -1.87 ± 
0.07; however, with a logD7.4 value of -2.19 ± 0.01, [
18
F]AlF-NOTA-ZHER3:8698 proved to be 
the most hydrophilic of the radioconjugates. 
 
Scheme 3. IEDDA ligation products of the reaction between [
18
F]AlF-3 and TCO-ZHER3:8698.  
 
 
In vitro stability studies. The stability of [
18
F]AlF-NOTA-ZHER3:8698 and [
18
F]AlF-NODA-
ZHER3:8698 was determined by incubating the radioconjugates in mouse serum at 37°C. By 
HPLC analysis, it was found that 97.9 ± 0.5% of [
18
F]AlF-NOTA-ZHER3:8698 and 91.5 ± 1.2% 
of [
18
F]AlF-NODA-ZHER3:8698 remained intact after 1 h (Figures S15). In both cases, the 
release of 
18
F (most probably in the form of the [
18
F]AlF complex) was observed as the main 
product of decomposition of the radioligands with [
18
F]AlF-NODA-ZHER3:8698 less stable to 
degradation. However, due to the short blood half-life of the affibody molecule, it is 
improbable that the breakdown of the radioconjugate would have a significant impact on its 
further in vivo validation.
45
 Notably, the HPLC trace of [
18
F]AlF-NODA-ZHER3:8698 (Figure 
S15B) shows the presence of two peaks (Peak 1 and Peak 2, Figure 3) corresponding to 
[
18
F]AlF-NODA-ZHER3:8698-Dihydropyridazine and [
18
F]AlF-NODA-ZHER3:8698-Pyridazine as 
previously described (Scheme 3). This confirms that the radioconjugate is present as a 
mixture in physiological conditions. A residual activity associated with the pelleted protein 
(20 ± 0.1% and 18.3 ± 2.3% for [
18
F]AlF-NOTA-ZHER3:8698 and [
18
F]AlF-NODA-ZHER3:8698 
respectively) shows some non-specific affinity of the radiotracers towards the serum protein. 
Having a less than 50% binding affinity value, both radioconjugates can be considered as low 
plasma protein binding compounds.
46
 
In vitro receptor binding. A saturation binding assay was performed to estimate the 
dissociation constant (Kd) of the two 
18
F-radiolabeled conjugates using high HER3-
expressing MCF-7 cells. The Kd was found to be 0.44 ± 0.04 nM for [
18F]AlF-NOTA-
ZHER3:8698 and 1.01 ± 0.28 nM for [
18F]AlF-NODA-ZHER3:8698 (Figure S18). Furthermore, a 
specificity of binding assay showed that both radiolabeled conjugates recognize the HER3 
receptor present on MCF-7 cells (Figure 4). A significant decrease in cell-associated 
radioactivity achieved by either pre-incubating MCF-7 cells with 100-fold molar excess of 
the non-radiolabeled affibody molecule or using low HER3-expressing MDA-MB-231 cells 
confirmed the target specificity (Figure 4). 
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Figure 4. In vitro binding specificity of [18F]AlF-NOTA-ZHER3:8698 (A) and [
18F]AlF-NODA-
ZHER3:8698 (B) to MCF-7 and MDA-MB-231 cells. The data are shown as the mean values of n 
= 3 experiments ± SEM. Statistical significance was determined with a two-way ANOVA 
with Tukey correction (
****
P < 0.0001).  
 
In vivo evaluation. The targeting properties of [18F]AlF-NOTA-ZHER3:8698 and [
18F]AlF-
NODA-ZHER3:8698 were evaluated in high HER3-expressing MCF-7 tumor-bearing mice. The 
biodistribution of both radioconjugates 1 h after injection displays similar in vivo behavior 
and pharmacokinetic profiles (Table 1). A relatively high accumulation in the tumor (4.36 ± 
0.92 and 4.96 ± 0.92 %ID/g for [18F]AlF-NOTA-ZHER3:8698 and [
18F]AlF-NODA-ZHER3:8698 
respectively) was found when 1 µg of protein (ca 0.8 MBq) was injected. The kidney uptake 
was high, resulting from the predominant renal excretion of the affibody molecule. This 
accumulation is the consequence of the reabsorption of the radiolabeled affibody molecule 
from the renal ultrafiltrate in the proximal tubules, where it is subsequently degraded. The 
radioactive metabolites are retained by the proximal tubular cells resulting in a renal 
accumulation of radioactivity over time.47 Both radioconjugates also showed high uptake in 
naturally HER3-expressing organs such as lungs, liver and intestine. Notably, [18F]AlF-
NODA-ZHER3:8698 showed an increased accumulation in the intestine (24.77 ± 13.96 %ID/g 
compared to 12.42 ± 3.35 %ID/g for [
18
F]AlF-NOTA-ZHER3:8698) suggesting that some 
hepatobiliary excretion might be involved in its clearance most likely due to the slightly 
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increased lipophilicity of [
18
F]AlF-NODA-ZHER3:8698. Similarly, blood, spleen, pancreas, bone 
and muscle uptakes were higher than those of [
18
F]AlF-NOTA-ZHER3:8698 (Table 1). However, 
in contrast to the other HER3 targeting affibody based radioligands reported in the literature, 
high-contrast images were achieved using both radioconjugates  already 1 h after injection.
22, 
23, 48
 The biodistribution pattern of [
18
F]AlF-NOTA-ZHER3:8698 produced tumor/blood, 
tumor/bone and tumor/muscle ratios of 24.61 ± 14.45, 20.86 ± 1.15, and 34.96 ± 8.60 
respectively which are higher than the values obtained for [
18
F]AlF-NODA-ZHER3:8698 (Table 
2).These findings suggest that [
18
F]AlF-NOTA-ZHER3:8698 may be considered the most 
promising candidate as HER3 imaging agent. Additionally, when low-HER3 expressing 
MDA-MB-231 tumor-bearing mice were injected with [
18
F]AlF-NOTA-ZHER3:8698 the tumor 
uptake was significantly reduced to 0.46 ± 0.02 %ID/g at 1 h p.i. (Table 1 and Figure 5) 
confirming the in vivo binding specificity of the radioconjugate. 
 
Table 1. Biodistribution results for [
18
F]AlF-NOTA-ZHER3:8698 and [
18
F]AlF-NODA-
ZHER3:8698 (0.8 MBq/mouse) at 1 h p.i. The data are reported as the mean percentage of the 
injected probe dose per gram of tissue (%ID/g) ± SD (for each group, n = 3). Statistical 
significance was determined with an unpaired t-test with Welch’s correction.  
 
 [
18
F]AlF-NODA-ZHER3:8698 [
18
F]AlF-NOTA-ZHER3:8698 
Tissue MCF-7 MCF-7 MDA-MB-231 
Blood 0.67 ± 0.47 0.25 ± 0.21 0.15 ± 0.04 
Heart 0.52 ± 0.30 0.23 ± 0.01 0.25 ± 0.07 
Lungs 2.05 ± 0.11 2.26 ± 0.88 2.42 ± 0.04 
Kidney 118.67 ± 2.85 134.78 ± 28.53 167.47 ± 1.83 
Spleen 0.43 ± 0.32 0.20 ± 0.03 0.23 ± 0.01 
Liver 6.92 ± 3.92 5.65 ± 0.92 7.23 ± 0.35 
Pancreas 1.97 ± 1.85 0.51 ± 0.24 0.85 ± 0.02 
Tumor 4.96 ± 0.65 4.36 ± 0.92 0.46 ± 0.02
a
 
Bone 0.38 ± 0.19 0.21 ± 0.06 0.21 ± 0.0001 
Small Intestine 24.77 ± 13.96 12.42 ± 3.35 25.16 ± 2.8 
Muscle 0.29 ± 0.10 0.13 ± 0.04 0.11 ± 0.01 
a
 Significantly lower uptake (P < 0.001) in MDM-MB-231 tumors. 
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Table 2. Tumor-to-organ ratios at 1h p.i. of [
18
F]AlF-NOTA-ZHER3:8698 and [
18
F]AlF-NODA-
ZHER3:8698.  
 
 [
18
F]AlF-NODA-ZHER3:8698 [
18
F]AlF-NOTA-ZHER3:8698 
Tissue MCF-7 MCF-7 
Blood 9.27 ± 4.02 24.61 ± 14.45 
Heart 11.10 ± 3.96 19.18 ± 5.10 
Lungs 2.42 ± 0.25 2.01 ± 0.34 
Kidney 0.04 ± 0.01 0.03 ± 0.01 
Spleen 14.99 ± 6.78 21.36 ± 1.60 
Liver 0.86 ± 0.42 0.77 ± 0.06 
Pancreas 3.90 ± 2.27 11.66 ± 9.75 
Tumor - - 
Bone 14.36 ± 4.81 20.86 ± 1.15 
Small Intestine 0.25 ± 0.13 0.36 ± 0.04 
Muscle 18.01 ± 3.31 34.96 ± 8.60 
 
The representative PET images of MCF-7 tumor-bearing mice at 1 h after injection of 
[18F]AlF-NOTA-ZHER3:8698 and [
18F]AlF-NODA-ZHER3:8698 are shown in Figure 5. Both 
radioconjugates, but in particular [18F]AlF-NOTA-ZHER3:8698, allowed a clear visualization of 
the tumor as a result of the high signal-to-noise ratio. In agreement with the biodistribution 
data, the signal intensity in the kidneys was very high in both cases.  
 
 
Figure 5. PET/CT images of MCF-7 tumor-bearing mice using [18F]AlF-NODA-ZHER3:8698 
and [18F]AlF-NOTA-ZHER3:8698. High contrast images were acquired as early as 1 h p.i. When 
[18F]AlF-NOTA-ZHER3:8698 was injected in low-HER3 expressing MDA-MB-231 tumor-
13 
 
bearing mice the tumor uptake was significantly reduced confirming the binding specificity 
of the radioconjugate. 
 
CONCLUSIONS 
 
Two strategies for the 
18
F-radiolabeling of the HER3-binding affibody molecule ZHER3:8698 
have been described: a conventional one-pot reaction at 100ºC using NOTA as chelator for 
the [18F]AlF complex, and an alternative two-step approach based on the IEDDA reaction 
using a novel tetrazine functionalized NODA and performed at room temperature. Both 
methods lead to an efficient incorporation of 18F and produced high purity radiolabeled 
products (RCP > 98%) after following the same purification procedure. Compared to 
conventional radiolabeling, the IEDDA approach helped avoid thermal degradation of the 
radioconjugate and can be used to radiolabel heat-sensitive compounds. However, this 
method generated multiple species, one of which was unreactive with the targeting affibody 
molecule. Although the successful tumor targeting and fast blood clearance of both 
radioconjugates ([18F]AlF-NOTA-ZHER3:8698 and [
18F]AlF-NODA-ZHER3:8698) enabled the 
clear visualization of high HER3-expressing MCF-7 tumors as early as 1 h p.i., the 
biodistribution of [18F]AlF-NODA-ZHER3:8698 was sub-optimal compared to [
18F]AlF-NOTA-
ZHER3:8698.  However, because of their equally high tumor uptake, studies to evaluate the 
effectiveness of either [
18
F]AlF-NOTA-ZHER3:8698 or [
18
F]AlF-NOTA-ZHER3:8698 to monitor 
anti-HER3 targeted therapies are on-going.  
 
EXPERIMENTAL PROCEDURES 
 
Conjugation of MMA-NOTA to ZHER3:8698-Cys affibody molecule. In a 1.5 mL low protein 
binding centrifuge tube, a solution of ZHER3:8698-Cys (300 µL, 1.6 mg/mL in PBS, 68.4 nmol) 
was diluted with PBS (130 µL) and EDTA 0.1 M solution (40 µL). A freshly prepared 
solution of TCEP-HCl (9.8 µL, 0.05 mg/µL in PBS, 1.71 µmol) was added and the mixture 
was incubated in a Thermomixer at 85°C for 5 min (800 rpm) followed by 25 min at room 
temperature. MMA-NOTA was then added (1.3 mg, 2.4 µmol) and the solution was 
incubated in a Thermomixer at 37°C for 2 h (800 rpm). The reaction mixture was analyzed by 
analytical reverse phase high performance liquid chromatography using gradient A 
(Supporting Information). The product was purified by semi-preparative RP-HPLC. The 
collected fractions containing the product were lyophilized and quantified by measuring the 
UV absorbance at 280 nm on a Nanodrop 2000 (310 µg, 61% yield). Analytical RP-HPLC: 
Rt = 8:32 (min:sec) MALDI-MS (m/z) : [M + H]
+
 expected: 7434, found: 7434.2 
 
Radiosynthesis of [
18
F]AlF-NOTA-ZHER3:8698. To a 1.5 mL low protein binding plastic tube 
containing the lyophilized NOTA-ZHER3:8698 (10 nmol), 2 mM AlCl3 (3.5-5.0 µl, 7-10 nmol) 
in 0.5 M NaOAc buffer pH 4, and aqueous non-purified 
18
F-fluoride (250-300 MBq), 
followed by an equal volume of ethanol, were added. The mixture was heated at 100°C for 15 
min. After cooling to ambient temperature, the solution was diluted with 0.1% aq TFA (50 
µl) and purified by RP-HPLC using Gradient A (Supporting Information): Rt = 8.53 
(min:sec). The collected fraction containing the product was diluted with 0.1% aq TFA (3 
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mL) and loaded on an Oasis HLB-SPE cartridge (1 mL, 30 mg). The trapped radioactivity 
was washed with 0.1% aq TFA (5 mL) and then eluted with of 50% ethanol/water (v/v, 100 
µl). The product was quantified by measuring the UV absorbance at 280 nm on a Nanodrop 
2000. Synthesis time (from the beginning of the reaction) = ca 50 min. The RCC (non-decay 
corrected) was expressed as the mean of n = 9 experiments ± SD. Protein recovery = 12.5-
42.6%; RCY = 9.9-27.4% 
 
Conjugation of TCO-PEG3-Maleimide to ZHER3:8698-Cys affibody molecule. In a low 
protein binding 1.5 mL low protein binding centrifuge tube, a solution of ZHER3:8698-Cys (300 
µL, 1.6 mg/mL in PBS, 68.4 nmol) was diluted with PBS (130 µL) and 0.1 M EDTA solution 
(40 µL). A freshly prepared solution of TCEP-HCl (9.8 µL, 0.05mg/µL in PBS, 1.71 µmol) 
was added and the mixture was incubated in a Thermomixer at 85°C for 5 min (800 rpm) 
followed by 25 min at 21°C. A solution of TCO-PEG3-Maleimide in DMSO (40 µL, 0.032 
mg/µL, 2.5 µmol) was then added and the solution was incubated in a Thermomixer at 37°C 
for 2 h (800 rpm). The reaction mixture was analyzed by analytical RP-HPLC and isolated by 
semi-preparative RP-HPLC using Gradient A (Supporting Information). The product, TCO-
ZHER3:8698, was lyophilized and quantified by measuring the UV absorbance at 280 nm on a 
Nanodrop 2000 (256.6 µg, 49.8% yield). Analytical RP-HPLC: Rt = 14:11 (min:sec). 
MALDI-MS (m/z) : [M + H]
+
 expected: 7534, found: 7534.0. 
 
Synthesis of 4-(6-methyl-1,2,4,5-tetrazin-3-yl)benzyl 4-methylbenzenesulfonate (2). A 
solution of p-toluenesulfonyl chloride (122 mg, 0.64 mmol) in DCM (10 mL) was added to 
compound 1 (87 mg, 0.43 mmol) followed by triethylamine (0.1 mL, 0.80 mmol). The 
reaction mixture was stirred at ambient temperature for 16 h. The solvent was removed in 
vacuo and the pink solid was purified by flash column chromatography on silica gel (40 - 63 
µm, 60 Å). EtOAc/hexane, 2:8) yielding compound 2 as pink powder (66 mg, 43% yield). 
1
H-NMR (500 MHz, CDCl3): δ = 8.55 (d, J = 8.5 Hz, 2H), 7.85 (d, J = 8.5 Hz, 2H), 7.49 (d, J 
= 8.3 Hz, 2H), 7.36 (d, J = 8.3 Hz, 2H), 5.16 (s, 2H), 3.11 (s, 3H), 2.45 (s, 3H). 
13
C-NMR 
(126 MHz, CDCl3): δ = 167.46, 163.64, 145.09, 137.92, 133.03, 132.30, 129.94, 128.88, 
128.15, 128.01, 70.85, 21.67, 21.19. ESI-MS (m/z): [M + H]
+
 calcd for C17H17N4O3S: 357.4, 
found: 357.10.  
 
Synthesis of 2,2'-(7-(4-(6-methyl-1,2,4,5-tetrazin-3-yl)benzyl)-1,4,7-triazonane-1,4-
diyl)diacetic acid (3). NO2AtBu (99 mg, 0.28 mmol) was added to a solution of compound 2 
(66 mg, 0.19 mmol) in acetonitrile (2 mL) followed by DIPEA (0.1 mL, 0.55 mmol) at 0 °C. 
The reaction was stirred for 24 h at room temperature. The solvent was removed in vacuo and 
TFA (2 mL) was added to the residue. The mixture was stirred at ambient temperature for 3 
h. The product was obtained by removing the TFA in vacuo as a red oily residue (47 mg, 
56% yield). For radiochemistry purposes, the product was further purified by semi-
preparative RP-HPLC using Gradient C (Supporting Information). The isolated product was 
lyophilized to yield a red oil (15 mg, 18% yield). 
1
H NMR (500 MHz, MeOD-d4) δ 8.63 (d, J 
= 8.5 Hz, 2H), 7.86 (d, J = 8.5 Hz, 2H), 4.45 (s, 2H), 3.58 (d, J = 20.4 Hz, 4H), 3.26–3.11 (m, 
6H), 3.07 (s, 3H), 3.02–2.91 (m, 4H), 2.87 (s, 2H). 13C NMR (126 MHz, MeOD-d4) δ 172.48, 
167.62, 163.53, 137.51, 133.05, 130.96, 127.96, 116.71, 99.99, 58.67, 54.64, 50.41, 49.51, 
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19.70. Analytical RP-HPLC (Gradient B): Rt = 9:03 (min:sec). ESI-HRMS: [M + H]
+
 (m/z) 
calcd for C20H28N7O4: 430.2203, found 430.2178. 
 
Radiosynthesis of [
18
F]AlF-3 and IEDDA reaction with TCO-ZHER3:8698. A mixture 
containing 3 in water (4 µL, 28 nmol), 2 mM AlCl3 in 0.5 M sodium acetate pH 4 (14 µL, 18-
28 nmol), non-purified 
18
F-fluoride (460-500 MBq) and an equal volume of EtOH (or 
acetonitrile, or tert-butanol) was incubated at 100 °C for 15 min. Analytical RP-HPLC 
(Gradient D, Supporting Information): Rt [
18
F]AlF-3 = 7.1 and 7.5 min. Specific activity = 
10.6-16.6 GBq/µmol (decay corrected to the end of reaction). 
The reaction solution containing [
18
F]AlF-3 was quickly added to lyophilized TCO-ZHER3:8698 
(3.5 nmol, 3 to TCO-ZHER3:8698 molar ratio 7:1) and the mixture was incubated at ambient 
temperature with mixing (800 rpm) for 17 min before purification by RP-HPLC using 
Gradient A (Supporting Information). The collected fraction containing the product was 
diluted with 0.1% aq TFA (3 mL) and loaded on an Oasis HLB-SPE cartridge. The trapped 
radioactivity was washed with 0.1% aq TFA (3 mL) and then eluted with 50% ethanol/water 
(v/v, 100 µl). The product was quantified by measuring the UV absorbance at 280 nm on a 
Nanodrop 2000. Synthesis time (from the beginning of the reaction) = ca 70 min. The RCC 
(non-decay corrected) was expressed as the mean of n = 12 experiments ± SD. Protein 
recovery = 34.0-54.8%  
 
In vitro serum stability assay.34 The stability of [18F]AlF-NOTA-ZHER3:8698 and [
18
F]AlF-
NODA-ZHER3:8698, with respect to change in RCP and loss of radioactivity from the affibody 
molecule, was assessed by incubating the purified [
18
F]AlF-radioconjugates (ca 4 MBq) in 
mouse serum (500 µL) in a Thermomixer at 37°C for 1 h (300 rpm). The mixture was then 
precipitated by addition of EtOH (300 µL) and centrifuged at 16000 × g for 2 min at 21°C. 
DMF (300 µL) was added to the supernatant which was then centrifuged at 16000 × g for 2 
min at 21°C. The supernatant was acidified with 0.1% aq TFA (300 µL), filtered through a 
0.2 µm Iso-Disc PVDF syringe filter and analyzed by RP-HPLC using Gradient A 
(Supporting Information). The radioactivity associated with the protein from the centrifuge 
spins was measured in a dose calibrator. Aqueous non-purified [
18
F]Fluoride solution (ca 4 
MBq) incubated in mouse serum (500 µL) was processed in the same way and used as 
control (to confirm the Rt of free [
18
F]Fluoride). The experiments were performed in 
triplicate. The data are expressed as the average of n = 3 measurements ± SEM. 
 
In vitro binding affinity and specificity of uptake of the radioconjugates. The dissociation 
constants (Kd) of the 
18
F-radiolabeled conjugates were assessed by a saturation binding assay 
using the high HER3-expressing MCF-7 cell line. The cells (5 × 10
5
) were plated on 12-well 
plates and cultured overnight. After removing the growth medium, the cells were washed 
with PBS and incubated with increasing concentrations of the radioconjugates (final 
concentrations of 0.01, 0.1, 0.5, 1.0, 2.5, 3.5, and 5.0 nM, ca 0.05-37 kBq/well) diluted in 
non-supplemented DMEM (1 mL). Non-specific binding was determined by pre-incubating 
the cells with 100-fold molar excess of the non-radiolabeled affibody molecule for 10 min. 
After 1 h incubation at 4°C, the cells were rinsed twice with PBS prior to detachment with 
trypsin-EDTA. Afterwards, the cells from each well were transferred to scintillation vials and 
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the total cell-associated radioactivity measured in a gamma counter. To estimate the Kd, the 
specific binding was determined by subtracting the fraction of non-specific binding from the 
total binding. The data were plotted as the amount (nM) of bound vs free radioconjugate. The 
binding curve was fitted to a one-site receptor-binding model using GraphPad Prism 6.00. 
The specificity of binding of each radioconjugate was evaluated using MCF-7 and MDA-
MB-231 cells (5 × 10
5
) plated on 12-well plates 24 h prior to the experiment. The cells were 
pre-incubated with a 100-fold molar excess of non-radiolabeled affibody molecule for 10 min 
at 4°C, followed by incubation with the radioconjugate (1 nM, ca 5 kBq/well) for 1 h at 4°C. 
The cells were rinsed twice with PBS, trypsinized, and collected into scintillation vials. The 
radioactivity was assessed using a gamma counter. The specificity of binding was normalized 
to the maximum cell-associated radioactivity per experiment and presented as mean of n = 3 
independent measurements ± SEM. 
 
In vivo evaluation. All experiments were performed in compliance with licenses issued 
under the UK Animals (Scientific Procedures) Act 1986 and following local ethical review. 
Studies were compliant with the United Kingdom National Cancer Research Institute 
Guidelines for Animal Welfare in Cancer Research.
49
 Female NCr athymic mice (6-8 week-
old) were subcutaneously injected on the shoulder with MCF-7 or MDA-MB-231 cells (7.5  
10
6
/mouse) suspended in 30% Matrigel. For MCF-7 cells, 17β-estradiol pellets (0.72 mg, 90 
days release) were implanted 48 h before cell inoculation, and remained in place until the end 
of the study. Tumors were allowed to grow for 3-4 weeks until reaching 100 mm
3
. PET/CT 
imaging studies were conducted using an Albira PET/SPECT/CT imaging system. Mice were 
administered the radioconjugate (1 µg in 100 L of 0.9% sterile saline, 0.7-0.8 MBq/mouse) 
by intravenous tail vein injection and approximately 5 minutes prior to imaging were 
anesthetized using isoflurane/O2 mixture (1.5-2.0 % v/v) and placed prone in the center of the 
scanner’s field of view. Whole body PET static images were acquired 1 h post radioconjugate 
injection for the duration of 10 min with a 358 to 664 keV energy window, followed by CT 
acquisition. The image data were normalized to correct for PET non-uniformity, dead-time 
count losses, positron branching ratio, and physical decay to the time of injection. No 
attenuation or partial-volume averaging corrections were applied. The PET images were 
reconstructed using a MLEM algorithm (12 iterations) with a voxel size of 0.5 × 0.5 × 0.5 
mm
3
. Whole body standard high resolution CT scans were performed with the X-ray tube set-
up at a voltage of 45 kV, current of 400 µA and 250 projections (1s per projection) and a 
voxel size of 0.5 × 0.5 × 0.5 mm
3
. The CT images were reconstructed using a FBP algorithm. 
Image analysis was performed using the PMOD software package. 
Immediately after the image data acquisition, the mice were euthanized by cervical 
dislocation for the biodistribution studies. The major organs/tissues were dissected, weighed, 
and the radioactivity was measured in a gamma counter. The percentage of the injected dose 
per gram of tissue (%ID/g) was determined for each organ/tissue. The data are expressed as 
the average of n = 3 mice ± SD. 
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Supporting Information 
 
The following supporting information is available: Materials and methods, analytical data for 
tetrazine (
1
H/
13
C NMR and ESI-HRMS) and affibody conjugates (MALDI-MS), RP-HPLC 
conditions and analytical RP-HPLC chromatograms, specific activities table, logD7.4 
determination, in vitro assays (serum stability and binding affinity), and general information 
about cell culture and the in vivo experiments. The material is available free of charge on the 
ACS Publication website http://pubs.acs.org 
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ABBREVIATIONS 
 
NOTA, 1,4,7-triazacyclononane-1,4,7-triacetate; NODA, 1,4,7-triazacyclononane-1,4-
diacetate; TCO, trans-cyclooctene; IEDDA; inverse-Electron Demand Diels-Alder; Kd, 
dissociation constant; RCC, radiochemical conversion; DTT, dithiothreitol; TCEP-HCl, 
tris(2-carboxyethyl)-phosphine hydrochloride; MWCO, molecular weight cut off; NO2AtBu, 
2,2'-(1,4,7-Triazacyclononane-1,4-diyl)diacetate; DIPEA, N,N-diisopropylethylamine; TFA, 
trifluoroacetic acid; RCP, radiochemical purity; SPE, solid phase extraction; SDS-PAGE, 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis; EDTA, 
ethylenediaminetetraacetic acid; p.i.. post injection; MMA-NOTA, maleimido-mono-amide 
NOTA; Rt, retention time; TCO-PEG3-Maleimide, trans-cyclooctene-(polyethylene glycol)3-
maleimide; NaOAc, sodium acetate; DMSO, dimethyl sulfoxide; DCM, dichloromethane; 
EtOAc, ethyl acetate; EtOH, ethanol; DMF; dimethylformamide; DMEM, Dulbecco’s 
modified eagle medium; HRG, heregulin; SEM, standard error of mean; MLEM, maximum 
likelihood expectation maximization; FBP, filtered backprojection; SD, standard deviation; 
RCY, radiochemical yield. 
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